AlphaRx Inc., of Markham, Ontario, received a notice of allowance for its patent application, titled "Stabilization of Benzoyl Peroxide in Solution."

Amazon Biotech Inc., of New York, received a notice of allowance for patent protection of its investigative drug, AMZ0026, a therapeutic herbal composition.

Chemokine Therapeutics Corp., of Vancouver, British Columbia, received U.S. Patent No. 7,091,310 B2, which relates to chemokine analogs for the treatment of human disease.

Curis Inc., of Cambridge, Mass., received U.S. Patent No. 7,115,653, titled "Small Organic Molecule Regulators of Cell Proliferation," which covers specific small-molecule agonists of the Hedgehog signaling pathway.

CV Therapeutics Inc., of Palo Alto, Calif., received a notice of allowance for a patent related to its biopolymer stent coating technology, which is being designed to improve the performance of stents coated with drugs such as paclitaxel or rapamycin.

DNAPrint Genomics Inc., of Sarasota, Fla., was granted a patent, titled "Methods for the Identification of Genetic Features for Complex Genetic Classifiers," relating to methods for identifying links between gene sequences and phenotypes.

Dyadic International Inc., of Jupiter, Fla., was granted U.S. Patent No. 7,122,330, titled "High-Throughput Screening of Expressed DNA Libraries in Filamentous Fungi." It expands protection for the C1 Host Technology Platform for applications in cellulosic ethanol and other markets.

Dynogen Pharmaceuticals Inc., of Waltham, Mass., was awarded U.S. Patent No. 7,115,606, which claims the use of DDP225 for the treatment of overactive bladder in patients who are not incontinent.

Ecopia BioSciences Inc., of Montreal, received U.S. Patent No. 7,101,872, directed for farnesyl dibenzodiazepinone and processes for its production, which relates to the company's lead cancer compound.

EntreMed Inc., of Rockville, Md., was issued U.S. Patent No. 7,081,477, titled "Estrogenic Compounds as Anti-Mitotic Agents," which covers claims of using 2-methoxyestradiol (2ME2) against diseases characterized by abnormal cell division.

GangaGen Inc., of Ottawa, Canada, received a patent for the invention of "Lysin-deficient bacteriophages having reduced immunogenicity," where they can be used to destroy pathogenic bacteria.

Idera Pharmaceuticals Inc., of Cambridge, Mass., was issued U.S. Patent No. 7,115,579, titled "Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides." It covers a method of inducing an immune response via administration of certain compounds that act through Toll-like receptors.

Isis Pharmaceuticals Inc., of Carlsbad, Calif., was issued U.S. Patent No. 7,108,974, covering the bacterial identification methodology used in the Ibis T5000 biosensor system.

Lpath Inc., of San Diego, received a notice of allowance for a patent covering the use of Sphingomab, a monoclonal antibody against sphingosine-1-phosphate, a bioactive lipid validated as a cancer target.

Nanogen Inc., of San Diego, was issued six patents, U.S. Patent Nos. 7,052,849; 7,049,397; 7,087,435; 7,026,129; 7,070,945; and 7,074,576. Those patents cover inventions related to diabetes and Alzheimer's disease and biomarkers.

Novelos Therapeutics Inc., of Newton, Mass., received a notice of allowance for its patent application extending the composition and method of use claims relating to NOV-002, its lead compound in Phase III development for non-small-cell lung cancer.

OncoMed Pharmaceuticals Inc., of Mountain View, Calif., was issued U.S. Patent No. 7,115,360, titled "Isolation and Use of Solid Tumor Stem Cells," covering an approach for testing of cancer stem-cell therapeutics to inhibit human tumor growth in preclinical models.

Ortec International Inc., of New York, received a notice of allowance for its patent related to its Haptides technology platform. The patent broadens the claims from one previously granted in June.

Quigley Corp., of Doylestown, Pa., said its wholly owned subsidiary Quigley Pharma received U.S. Patent No. 7,083,813 B2, titled "Methods for The Treatment of Peripheral Neural and Vascular Ailments." Claims relate to its lead investigational drug, QR-333, in Phase II trials.

No Comments